<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1012-2966</journal-id>
<journal-title><![CDATA[Gaceta Médica Boliviana]]></journal-title>
<abbrev-journal-title><![CDATA[Gac Med Bol]]></abbrev-journal-title>
<issn>1012-2966</issn>
<publisher>
<publisher-name><![CDATA[Facultad de Medicina de la Universidad Mayor de San Simón]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1012-29662025000200102</article-id>
<article-id pub-id-type="doi">10.47993/gmb.v48i2.1000</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Marcadores CA 15-3 y CEA en mama]]></article-title>
<article-title xml:lang="en"><![CDATA[CA 15-3 and CEA markers in the breast]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Condori Flores]]></surname>
<given-names><![CDATA[Liz Nela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mamani Garabito]]></surname>
<given-names><![CDATA[Jhanneth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Adventista de Bolivia Facultad de Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Bolivia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>48</volume>
<numero>2</numero>
<fpage>102</fpage>
<lpage>106</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1012-29662025000200102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1012-29662025000200102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1012-29662025000200102&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer de mama es una de las principales causas de morbilidad y mortalidad en mujeres a nivel mundial. Su aparición se relaciona con factores demográficos, reproductivos y de estilo de vida, por lo que resulta fundamental fortalecer las estrategias de detección temprana y seguimiento clínico. Los marcadores tumorales CA 15-3 y CEA se emplean para evaluar la actividad tumoral y apoyar el control de la enfermedad.  Objetivo:  determinar los marcadores tumorales CA 15-3 - CEA en pacientes con cáncer de mama en el instituto oncológico nacional de Cochabamba Bolivia.  Métodos:  es un estudio de un enfoque cuantitativo de tipo descriptivo y correlacional y de diseño no experimental de corte transversal, fue de 89 pacientes con diagnóstico de cáncer de mama que acudieron al Instituto Oncológico Nacional.  Resultados:  el 27,0% de los pacientes presentó valores positivos para el marcador CEA, y el 20,2% fue positivo para CA 15-3. Con respecto al sexo, el 25,8% de las mujeres fue positivo para CEA y solo el 1,1% de los hombres. Para CA 15-3, el 19,2% de las mujeres mostró niveles elevados y el 1,0% de los hombres, no existe correlación significativa entre el sexo y los marcadores tumorales. Aunque el grupo etario de 41 a 50 años refleja principalmente la actividad tumoral más que la edad.  Conclusión:  los marcadores CA 15-3 y CEA son útiles en el seguimiento clínico de pacientes con cáncer de mama; sin embargo, no se encontró una correlación estadísticamente significativa con las variables evaluadas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Breast cancer is a leading cause of morbidity and mortality in women worldwide. Its occurrence is linked to demographic, reproductive, and lifestyle factors, making it essential to strengthen early detection and clinical follow-up strategies. The tumor markers CA 15-3 and CEA are used to assess tumor activity and support disease management.  Objective:  to determine the tumor markers CA 15-3 and CEA in breast cancer patients at the National Cancer Institute of Cochabamba, Bolivia. Methods: This was a quantitative, descriptive, and correlational study with a non-experimental, cross-sectional design. The study included 89 patients diagnosed with breast cancer who attended the National Cancer Institute.  Results:  27.0% of patients tested positive for the CEA marker, and 20.2% tested positive for CA 15-3. Regarding sex, 25.8% of women tested positive for CEA and only 1.1% of men. For CA 15-3, 19.2% of women showed elevated levels and 1.0% of men; no significant correlation was found between sex and tumor markers. The 41-50 age group was more frequently affected, reflecting tumor activity rather than age.  Conclusion:  The CA 15-3 and CEA markers are useful in the clinical follow-up of breast cancer patients; however, no statistically significant correlation was found with the variables evaluated.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[antígeno carcinoembrionario]]></kwd>
<kwd lng="es"><![CDATA[marcadores tumorales biológicos]]></kwd>
<kwd lng="es"><![CDATA[neoplasias de la mama]]></kwd>
<kwd lng="en"><![CDATA[carcinoembryonic antigen]]></kwd>
<kwd lng="en"><![CDATA[breast neoplasms]]></kwd>
<kwd lng="en"><![CDATA[biological tumor markers]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ciruelos]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Jerusalem]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mueller]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Niikura]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Viale]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LBA18 Trastuzumab deruxtecan (T-DXd) in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: primary results of DESTINY-Breast12]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2024</year>
<volume>35</volume>
<numero>Suppl 2</numero>
<issue>Suppl 2</issue>
<page-range>S1211-2</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Momenimovahed]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Salehiniya]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological characteristics and risk factors of breast cancer in the world]]></article-title>
<source><![CDATA[Breast Cancer (Dove Med Press)]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>151-64</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loibl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Poortmans]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Denkert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Curigliano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>397</volume>
<numero>10286</numero>
<issue>10286</issue>
<page-range>1750-69</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolarz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Nowak]]></surname>
<given-names><![CDATA[AZ]]></given-names>
</name>
<name>
<surname><![CDATA[Romanowicz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer: epidemiology, classification, pathogenesis and treatment (review of literature)]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2022</year>
<volume>14</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonilla-Sepúlveda]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marcadores tumorales en cáncer de mama. Revisión sistemática]]></article-title>
<source><![CDATA[Ginecol Obstet Mex]]></source>
<year>2020</year>
<volume>88</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>860-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Devora]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<source><![CDATA[Marcadores tumorales en cáncer de mama: CA 15-3 y antígeno carcinoembrionario]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Babahoyo ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Técnica de Babahoyo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naranjo Pintado]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
</person-group>
<source><![CDATA[Determinación del marcador tumoral CA 15.3 como medida preventiva para la detección de cáncer de mama en mujeres universitarias durante el año 2018]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Central del Ecuador, Facultad de Ciencias Médicas, Carrera de Laboratorio Clínico e Histotecnológico]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saldivia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Baez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Valor predictivo del CA 15-3 como marcador tumoral en cáncer de mama]]></article-title>
<source><![CDATA[Rev Venez Oncol]]></source>
<year>2006</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>92-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mora]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Marcadores tumorales]]></article-title>
<source><![CDATA[Rev Cienc Salud Integrando Conoc]]></source>
<year>2018</year>
<volume>2</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<collab>American Society of Clinical Oncology</collab>
<source><![CDATA[Breast cancer: statistics]]></source>
<year>2012</year>
<publisher-name><![CDATA[Cancer.Net]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canché Chan]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
</person-group>
<source><![CDATA[Utilidad de los marcadores tumorales CA 15-3 y CA 27.29 en pacientes con cáncer de mama]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Mexico City ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Valdés Rodríguez]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Polo Vega]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Marcel]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del marcador tumoral CEA y el CA 15-3 en pacientes con cáncer de mama]]></article-title>
<source><![CDATA[Rev Latinoam Patol Clin Med Lab]]></source>
<year>2015</year>
<volume>62</volume>
<page-range>127-34</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<collab>MedlinePlus</collab>
<source><![CDATA[Examen de sangre ELISA: enciclopedia médica]]></source>
<year></year>
<publisher-loc><![CDATA[Bethesda (MD) ]]></publisher-loc>
<publisher-name><![CDATA[U.S. National Library of Medicine]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>ReactLab</collab>
<source><![CDATA[CA 15-3]]></source>
<year></year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[ReactLab]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>ReactLab</collab>
<source><![CDATA[CEA]]></source>
<year></year>
<publisher-loc><![CDATA[Quito ]]></publisher-loc>
<publisher-name><![CDATA[ReactLab]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</collab>
<source><![CDATA[Sitio web del Comité de Ética en Investigación]]></source>
<year></year>
<publisher-loc><![CDATA[Mexico City ]]></publisher-loc>
<publisher-name><![CDATA[INCMNSZ]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López Ruiz]]></surname>
<given-names><![CDATA[DJA]]></given-names>
</name>
<name>
<surname><![CDATA[Zabalza Estévez]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
<name>
<surname><![CDATA[Mieza Arana]]></surname>
<given-names><![CDATA[DJA]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre Larracoechea]]></surname>
<given-names><![CDATA[DU]]></given-names>
</name>
<name>
<surname><![CDATA[Vivanco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López Maseda]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinación del perfil de expresión génica (70 genes) en cáncer de mama: ¿son apropiadas las muestras obtenidas en la biopsia percutánea diagnóstica?]]></article-title>
<source><![CDATA[Seram]]></source>
<year>2022</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryu]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic impact of elevated cancer antigen 15-3 (CA15-3) in early breast cancer patients with normal serum CA15-3 levels]]></article-title>
<source><![CDATA[J Breast Cancer]]></source>
<year>2023</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>126-35</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawsar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kawser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hossain]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<source><![CDATA[Recurrence of breast cancer among Bangladeshi women using two serum protein tumor markers, carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3): a prospective observational study]]></source>
<year>2023</year>
<publisher-name><![CDATA[ResearchGate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fakhari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gharepapagh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dabiri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gilani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlation of cancer antigen 15-3 (CA15-3) serum level and bony metastases in breast cancer patients]]></article-title>
<source><![CDATA[Med J Islam Repub Iran]]></source>
<year>2019</year>
<volume>33</volume>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of serum CA15-3 and carcinoembryonic antigen levels in patients with breast cancer: a meta-analysis]]></article-title>
<source><![CDATA[Med Sci Monit]]></source>
<year>2016</year>
<volume>22</volume>
<page-range>3154-62</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Augé]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Escudero]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Filella]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zanon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pahisa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of tumor markers (HER-2/neu oncoprotein, CEA and CA 15.3) in locoregional breast cancer patients: prognostic value]]></article-title>
<source><![CDATA[Tumour Biol]]></source>
<year>2010</year>
<volume>31</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>171-80</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
